Dry powder nebulizer developer Nob Hill Therapeutics announced the appointment of Noel Greenberger as its new CEO, replacing interim CEO Yun Li as of September 1, and said that it has received a Department of Health and Human Services (HHS) Small Business Innovation Research (SBIR) Phase 2 grant of up to $1.73 million for development of a dry powder antifungal … [Read more...] about Nob Hill names Noel Greenberger as CEO, gets $1.7 million grant for development of a nebulized dry powder antifungal
News
SaNOtize raises $24 million for development of NONS nitric oxide nasal spray
SaNOtize announced that it has closed a $24 million Series B funding round led by Horizons Ventures and OurCrowd with proceeds to go towards continued development of the company’s NONS nitric oxide nasal spray. The company initiated a Phase 3 trial of NONS for the treatment of COVID-19 in June 2021 and announced positive results from that study in July 2022. In August … [Read more...] about SaNOtize raises $24 million for development of NONS nitric oxide nasal spray
FDA approves Lupin’s formoterol fumarate inhalation solution
According to Lupin, the FDA has approved the company's ANDA for a generic version of Mylan's Perforomist formoterol fumarate inhalation solution. Teva launched a generic equivalent in the US in June 2021 after expiration of the final patent covering Perforomist, and the agency approved Alembic Pharmaceuticals' ANDA for its Perforomist equivalent in November 2021. … [Read more...] about FDA approves Lupin’s formoterol fumarate inhalation solution
Lee’s acquires global rights to Windtree’s Aerosurf aerosolized KL4 surfactant
Windtree Therapeutics said that it has signed a deal with Lee’s Pharmaceutical and its subsidiary Zhaoke Pharmaceutical giving Lee's global rights to develop and commercialize Windtree surfactants for any potential indications, including Aerosurf aerosolized KL4 surfactant for the treatment of premature infants with respiratory distress syndrome. According to … [Read more...] about Lee’s acquires global rights to Windtree’s Aerosurf aerosolized KL4 surfactant
Nuance Pharma gets the go-ahead for clinical trials of nebulized ensifentrine in China
According to Nuance Pharma, the Chinese Center for Drug Evaluation has approved the company's IND, allowing for a Phase 3 trial of nebulized ensifentrine, a PDE3/PDE4 inhibitor for the treatment of COPD, in China. The IND also grants approval for a Phase 1 PK study in healthy volunteers that the company plans to conduct in China. Nuance acquired the Chinese rights to … [Read more...] about Nuance Pharma gets the go-ahead for clinical trials of nebulized ensifentrine in China
NIH announces availability of licensing for IP related to nebulized thrombin inhibitors for the treatment of SARS-CoV-2-induced lung fibrosis
The US National Institutes of Health (NIH) has published a notice in the Federal Register regarding the availability of intellectual property related to the use of inhaled thrombin inhibitors for the treatment of lung fibrosis caused by SARS-CoV-2 infection. The notice says that the technology "is available for licensing to achieve expeditious commercialization of … [Read more...] about NIH announces availability of licensing for IP related to nebulized thrombin inhibitors for the treatment of SARS-CoV-2-induced lung fibrosis
Respira Technologies names Brian Quigley as CEO
California-based nebulizer developer Respira Technologies has announced that Chief Operating Officer Brian Quigley will replace company founder Mario Danek as CEO, and Danek will take over the role of Chief Technology Officer. Quigley joined the company in 2020 after having spent most of his career in various positions at tobacco company Altria, including a stint … [Read more...] about Respira Technologies names Brian Quigley as CEO
Pneumagen initiates Phase 2 challenge study of Neumifil nasal spray against flu
Pneumagen announced the initiation of a Phase 2 challenge study of its Neumifil multivalent carbohydrate binding module (mCBM) nasal spray, which is the company is developing as a universal treatment for influenza, RSV, and COVID-19. The Phase 2 trial is expected to enroll up to 100 subjects who will receive one of two dose levels of Neumifil or a placebo nasal spray … [Read more...] about Pneumagen initiates Phase 2 challenge study of Neumifil nasal spray against flu
Positive Phase 3 results for Bharat Biotech’s BBV154 intranasal COVID-19 vaccine
According to Bharat Biotech, two recently completed Phase 3 trials of its BBV154 intranasal COVID-19 vaccine demonstrated the safety and tolerability of the recombinant replication-deficient adenovirus vectored vaccine and as well as its ability to elicit an immune response. One of the trials enrolled approximately 3100 subjects who received either two doses of BBV154 … [Read more...] about Positive Phase 3 results for Bharat Biotech’s BBV154 intranasal COVID-19 vaccine
HDT Bio Gets $1.8 million for US Army for development of antiviral nasal spray
HDT Bio announced that it has received a grant of ~$1.8 million from the US Army Medical Research Acquisition Activity for development of the company's HDT-201 RNA-based nasal spray for the prevention and treatment of viral infections. The company said that the funding will support pre-clinical safety and potency studies, with clinical trials anticipated to begin in … [Read more...] about HDT Bio Gets $1.8 million for US Army for development of antiviral nasal spray